3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
pembrolizumab
91
Blood Specimen Collection
44
Cyclophosphamide
37
Nivolumab
36
Bevacizumab
36
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
28
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
24
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Oxaliplatin
19
Docetaxel
19
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Biopsy
15
130-nm albumin-bound paclitaxel
15
Prednisone
14
Ipilimumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
1 year
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled